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Fibroblast growth factor 21 (FGF21) is a fasting-
induced hepatokine that has potent pharmacologic
effects in mice, which include improving insulin
sensitivity and blunting growth. The single-trans-
membrane protein bKlotho functions as a coreceptor
for FGF21 in vitro. To determine if bKlotho is required
for FGF21 action in vivo, we generated whole-body
and adipose tissue-selective bKlotho-knockout
mice. All of the effects of FGF21 on growth and
metabolism were lost in whole-body bKlotho-
knockout mice. Selective elimination of bKlotho in
adipose tissue blocked the acute insulin-sensitizing
effects of FGF21. Taken together, these data demon-
strate that bKlotho is essential for FGF21 activity and
that bKlotho in adipose tissue contributes to the
beneficial metabolic actions of FGF21.
INTRODUCTION
Fibroblast growth factor 21 (FGF21) is a member of an atypical
subfamily of FGFs, including FGF15/19 and FGF23, that can
circulate as hormones (Potthoff et al., 2012). In rodents, FGF21
expression is strongly induced in liver by fasting through a
peroxisome proliferator-activated receptor (PPAR) a-dependent
mechanism (Badman et al., 2007; Inagaki et al., 2007; Lundasen
et al., 2007). Consistent with a role in the response to long-term
fasting and starvation, FGF21 stimulates hepatic fatty acid
oxidation, ketogenesis, and gluconeogenesis while inhibiting
somatic growth in lean mice (Badman et al., 2007, 2009; Inagaki
et al., 2007, 2008; Potthoff et al., 2009). Fgf21 is also induced in
white adipose tissue (WAT) by fasting/refeeding regimens and
PPARg agonists (Dutchak et al., 2012; Muise et al., 2008; Oishi
et al., 2011; Wang et al., 2008), and in brown adipose tissue
(BAT) by cold exposure (Chartoumpekis et al., 2011; Hondares
et al., 2011). In WAT, FGF21 acts in an autocrine fashion to regu-
late PPARg activity (Dutchak et al., 2012) and to stimulate
a thermogenic response (Fisher et al., 2012). In obese rodents
and monkeys, FGF21 administration improves insulin sensitivity,
normalizes triglyceride and cholesterol levels, and causesweightCell Meloss (Coskun et al., 2008; Kharitonenkov et al., 2005, 2007; Xu
et al., 2009). Thus, FGF21 is a promising drug candidate for
treating human metabolic disease.
In vitro studies showed that FGF21 and FGF15/19 act through
a cell-surface receptor complex composed of conventional FGF
receptors and bKlotho, a single-pass transmembrane protein
(Kharitonenkov et al., 2008; Ogawa et al., 2007; Suzuki et al.,
2008). FGF21 interacts directly with the extracellular domain of
bKlotho in the FGFR/bKlotho complex and activates FGF
receptor substrate 2a and ERK1/2 phosphorylation. Whereas
the FGFRs are expressed in most tissues, bKlotho expression
is restricted to just a few, including liver and both WAT and
BAT (Fon Tacer et al., 2010). FGF21 modulates the expression
of metabolic genes in each of these tissues (Coskun et al., 2008).
Mice lacking bKlotho in all tissues are viable and fertile (Ito
et al., 2005). However, these bKlotho-knockout (KO) mice are
smaller than their wild-type counterparts and have increased
hepatic bile acid synthesis and smaller gallbladders. The latter
two phenotypes are consistent with the established roles of
FGF15/19 in repressing hepatic bile acid synthesis and stimu-
lating gallbladder filling. Subsequent studies showed that
bKlotho-KO mice are refractory to the effects of FGF19 on
gene expression in liver and other tissues (Tomiyama et al.,
2010). While these results demonstrate that bKlotho is required
for FGF15/19 action, to date there is no corresponding in vivo
evidence that bKlotho is required for FGF21 action. Indeed,
a recent study suggested that bKlotho is not required for
FGF21 to induce expression of the transcription factor, early
growth response 1 (EGR1), in WAT and BAT (Tomiyama et al.,
2010), leaving the relationship between FGF21 and bKlotho in
question. In this study, we have examined the requirement of
bKlotho for FGF21 action. We show that mice lacking bKlotho
are resistant to both acute and chronic effects of FGF21. We
further show that bKlotho in adipose tissue is crucial for the acute
insulin-sensitizing actions of FGF21.
RESULTS AND DISCUSSION
bKlotho Is Required for Acute Effects of FGF21
To generate global bKlotho-KO mice, loxP recombination sites
were introduced flanking exon 1 of the bKlotho (Klb) gene, which
encodes the start codon and first 275 amino acids of the protein
(see Figures S1A and S1B online). Mice heterozygous for thetabolism 16, 387–393, September 5, 2012 ª2012 Elsevier Inc. 387
Figure 1. bKlotho Is Required for Acute
Actions of FGF21
(A) QPCR analysis of bKlotho (Klb) mRNA in inter-
scapular brown adipose tissue (BAT), epididymal
white adipose tissue (eWAT), and liver of Klb
heterozygous (HET) or knockout (KO)mice (n = 4–5
mice/group). n.d., not detected (Ct > 36).
(B) Western blot of bKlotho protein in interscapular
BAT, epididymal WAT, and liver. b-actin was
included as a loading control.
(C) QPCR analysis of Egr1 mRNA in interscapular
BAT, epididymal WAT, and liver 1 hr after vehicle
(Veh) or FGF21 injection (1 mg/kg, intraperitoneal
injection) (n = 5–6 mice/group). Different letters
indicate a significant difference (p < 0.05).
(D) Insulin tolerance tests (0.75 U/kg insulin) in
mice coinjected with vehicle or FGF21 (1 mg/kg,
intraperitoneal injection) (n = 4–5 mice/group).
*p < 0.05, **p < 0.01, ***p < 0.005 between groups
of HET and KO mice treated with FGF21.
(E) Tissue glucose uptake assay in male C57Bl/6
mice coinjected with insulin (0.75 U/kg) and
vehicle or insulin and FGF21 (1 mg/kg, intraperi-
toneal injection) (n = 4 mice/group). Gastroc.,
gastrocnemius; BAT, brown adipose tissue;
eWAT, epididymal white adipose tissue.
Data are presented as the mean ± SEM.
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transgene, which deletes in the germline, to generate Klb+/–
heterozygous (HET) mice. The HET mice were then intercrossed
to yield Klb/ (KO) mice. No KlbmRNA or protein was detected
in BAT, WAT, or liver from KO mice (Figures 1A and 1B). Con-
sistent with a previous report (Tomiyama et al., 2010), Fgf15
expression was significantly increased in the ileum in KO mice
(Figure S1C). Fgf21 mRNA in the liver and protein in the plasma
also trended higher in the KO mice (Figure S1C).
We examined whether bKlotho is required for FGF21 signaling
in BAT, WAT, and liver. To generate sufficient numbers of mice
for these and subsequent studies, HET-KO crosses were bred
to yield HET and KO progeny, which were then compared. As
expected (Fisher et al., 2010; Tomiyama et al., 2010), FGF21
injection induced Egr1 expression in BAT, WAT, and liver of
HET mice (Figure 1C). The effect of FGF21 on Egr1 expression
was lost in KO mice. These data show that bKlotho is required
for the acute effect of FGF21 on Egr1 expression in multiple
tissues.
We next tested whether bKlotho is required for the acute
insulin-sensitizing actions of FGF21. Coinjection of insulin and
FGF21 into HET mice caused a decrease in blood glucose levels
that was not seen when insulin was injected with vehicle alone
(Figure 1D). Importantly, this insulin-sensitizing effect of FGF21
was lost in KO mice. Thus, bKlotho is required for the acute
insulin-sensitizing actions of FGF21. In complementary experi-388 Cell Metabolism 16, 387–393, September 5, 2012 ª2012 Elsevier Inc.ments, we measured the effect of
FGF21 on tissue-specific glucose uptake
under these same ITT conditions. As
shown in Figure 1E, FGF21 significantly
induced glucose uptake in BAT but not
WAT or gastrocnemius or soleus skeletal
muscle in wild-type mice 30 min afterinjection. These data demonstrate that BAT contributes to the
acute glucose-lowering effect of FGF21.
bKlotho Is Required for Chronic FGF21 Actions
To determine whether bKlotho is required for long-term FGF21
action, KO mice were crossed with Fgf21-transgenic (Tg) mice
(Inagaki et al., 2007) to generate four genotypes: HET, HET/Tg,
KO, and KO/Tg mice. As expected, HET/Tg mice weighed less
and had shorter tibiae than HET mice (Figures 2A and 2B), which
is consistent with FGF21 inhibiting growth (Inagaki et al., 2008;
Kubicky et al., 2012). KOmice also weighed less and had shorter
tibiae than HET mice, demonstrating that bKlotho is required for
normal growth as previously described (Ito et al., 2005). Notably,
the effects of transgenic FGF21 overexpression on body weight
and tibia length were lost in KO/Tg mice (Figures 2A and 2B).
FGF21 overexpression also increased food intake, lowered
body fat content, and increased lean body content in HET
mice but not in KO mice (Figures 2C and 2D). Thus, bKlotho is
required for the effects of FGF21 on growth and body composi-
tion in lean mice.
Long-term treatment of obese mice with FGF21 suppresses
weight gain and improves insulin sensitivity and other metabolic
parameters (Coskun et al., 2008; Kharitonenkov et al., 2005; Xu
et al., 2009). To determine if bKlotho is required for these effects,
groups of HET, HET/Tg, KO, and KO/Tg mice were fed a high-fat
diet (HFD). HET/Tg mice gained weight more slowly on the HFD
Figure 2. bKlotho Is Required for Chronic Actions of FGF21
(A) Body weight in normal chow-fed, 4-month-old Klb+/– (HET) or Klb–/– (KO) mice either expressing or not expressing the Fgf21 transgene (Tg) (n = 33 for HET;
n = 35 for HET/Tg; n = 13 for KO; n = 15 for KO/Tg).
(B) Tibia length in 5- to 8-month-old mice (n = 16 for HET; n = 13 for HET/Tg; n = 10 for KO; n = 11 for KO/Tg).
(C) Food intake in 4- to 7-month-old mice fed normal chow (n = 7–9 mice/group).
(D) Body composition in 4- to 7-month-old mice fed normal chow (n = 7–9 mice/group).
(E) Body weight change during a 3 month high-fat diet (HFD) in 4- to 7-month-old HET, HET/Tg, KO, and KO/Tg mice (n = 7–9 mice/group). *p < 0.05 between
HET/Tg and KO/Tg mice.
(F) Body composition after 2 months on a HFD (n = 7–9/group).
(G) Liver:lean mass ratio after 3 months on a HFD (n = 7–9 mice/group).
(H) Liver lipid levels after 3 months on a HFD (n = 7–9 mice/group).
(I) Liver appearance after 3 months on a HFD.
(J) Oil red O staining of liver samples after 3 months on a HFD.
(K) Intraperitoneal glucose tolerance test (IPGTT) after a 10 week HFD (n = 6 mice/group). *p < 0.05 between HET/Tg and KO/Tg groups.
(L) Insulin tolerance test (ITT) after an 8 week HFD (n = 6 mice/group). *p < 0.05 between HET/Tg and KO/Tg groups.
Data are presented as the mean ± SEM. For (A)–(D) and (F)–(H), different letters indicate a significant difference (p < 0.05).
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Table 1. Deletion of bKlotho Eliminates the Effects of FGF21 on Plasma Carbohydrate and Lipid Parameters
HET HET/Tg KO KO/Tg
NEFA (mM) 0.48 ± 0.02 0.36 ± 0.01** 0.47 ± 0.03 0.41 ± 0.02#
Triglyceride (mg/dl) 87.4 ± 5.0 74.9 ± 4.5 70.3 ± 4.4y 68.0 ± 4.0
Cholesterol (mg/dl) 266.3 ± 16.2 169.1 ± 8.2** 196.2 ± 9.2yyy 175.5 ± 10.1
Leptin (ng/ml) 57.7 ± 9.6 10.2 ± 1.7** 68.1 ± 14.1 68.9 ± 14.9###
Adiponectin (mg/ml) 10.3 ± 2.5 24.1 ± 3.6* 10.1 ± 1.1 6.8 ± 1.4###
Insulin (ng/ml) 15.6 ± 4.4 1.5 ± 0.3* 9.1 ± 3.5 9.2 ± 3.0#
Glucose (mg/dl) 206.5 ± 10.5 161.9 ± 5.4** 198.3 ± 5.8 203.3 ± 11.7###
Plasma parameters weremeasured in diet-induced obese HET, HET/Fgf21-Tg,Klb–/– (KO), andKO/Fgf21-Tgmice after a 3month HFD (n = 7–23). Data
are presented as themean ±SEM. *p < 0.01, **p < 0.005 betweenHET andHET/Tg. #p < 0.05, ###p < 0.005 betweenHET/Tg and KO/Tg. yp < 0.05, yyyp <
0.005 between HET and KO.
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ure 2E, Figures S2A and S2B). MRI measurements done after
2 months on the HFD showed that HET/Tg mice had reduced
percent fat mass and increased percent lean mass compared
to the other three genotypes (Figure 2F). Consistent with these
findings, plasma leptin concentrations were lower in HET/Tg
mice compared to all the other groups, while plasma adiponectin
concentrations were higher (Table 1). The liver weight:lean mass
ratio was reduced, and hepatic lipids, including triglyceride and
cholesterol, were lower in HET/Tg mice compared to the other
groups (Figures 2G–2J). HET/Tg mice also had reduced plasma
cholesterol concentrations (Table 1). These findings show that
bKlotho is required for the effects of FGF21 on body composition
and lipid homeostasis in HFD-fed mice.
We also examined the role of bKlotho in carbohydrate homeo-
stasis. HET/Tgmice hadmarkedly lower fed-state plasma insulin
and glucose concentrations comparedwith HET, KO, and KO/Tg
mice (Table 1). In glucose tolerance tests, HET/Tg mice had
a reduced glucose excursion compared to the other groups (Fig-
ure 2K). In insulin tolerance tests, HET/Tg mice showed a much
more pronounced decrease in glucose levels than HET, KO, and
KO/Tg mice (Figure 2L). We conclude that bKlotho is required for
the effects of FGF21 on carbohydrate homeostasis, including its
insulin-sensitizing actions.
We next compared the expression of metabolic genes in BAT,
WAT, and liver of HET, HET/Tg, KO, and KO/Tg mice. In BAT,
uncoupling protein-1 (Ucp1), deiodinase 2 (Dio2), and elongation
of very long chain fatty acids like-3 (Elovl3) were elevated in
HET/Tg compared to HET mice (Figure S2C). In epididymal
WAT (eWAT), peroxisome proliferator-activated receptor g
coactivator 1a (Pgc1a), phosphoenolpyruvate carboxykinase
(Pck1), acetyl-CoA carboxylase a (Acaca), stearoyl-Coenzyme
A desaturase 1 (Scd1), adiponectin (Adipoq), and resistin
(Retn) were increased in HET/Tg compared to HET mice (Fig-
ure S2D). In subcutaneous WAT (scWAT), Ucp1, Pgc1a, Pck1,
Acaca, Scd1, and resistin Retn were increased in HET/Tg
compared to HET mice (Figure S2E). The finding that FGF21
induces Ucp1 in scWAT is in agreement with a recent report in
which it was shown that FGF21 efficiently stimulates the brown-
ing of inguinal and perirenal WAT (Fisher et al., 2012). In liver,
Pgc1a was increased and fatty acid synthase (Fasn), Scd1,
Acaca, Cd36, and Elovl6 were decreased in HET/Tg compared
to HETmice (Figure S2F). Notably, all of these FGF21-dependent
changes in gene expression were lost in the KO background390 Cell Metabolism 16, 387–393, September 5, 2012 ª2012 Elsevie(Figures S2C–S2F). Thus, bKlotho is essential for FGF21 to exert
its effect on metabolic gene expression in multiple tissues.
bKlotho in Adipose Is Required for the Acute
Insulin-Sensitizing Actions of FGF21
WAT and BAT are well-documented targets of FGF21 expres-
sion and activity (Chartoumpekis et al., 2011; Dutchak et al.,
2012; Hondares et al., 2011; Kharitonenkov et al., 2005; Muise
et al., 2008; Oishi et al., 2011; Wang et al., 2008). To begin to
assess the contributions of adipose tissue to the pharmacologic
actions of FGF21, we crossed Klbfl/fl mice with aP2-Cre mice,
which express Cre in adipose tissue, to yield Klbfl/fl;aP2-Cre
(KOaP2) mice. Klb mRNA was almost entirely absent in BAT,
reduced by 70% in WAT, and unchanged in liver of KOaP2
mice (Figure 3A). Western blot analysis confirmed that these
changes inKlbmRNA caused corresponding changes in bKlotho
protein (Figure S3A). Injection of KOaP2micewith FGF21 induced
Egr1 in liver but not in BAT (Figure S3B). FGF21-mediated induc-
tion ofEgr1was also reduced inWATof KOaP2mice (Figure S3B),
coincident with the reduction of bKlotho (Figure 3A). KOaP2 mice
had normal body weight and composition (Figure S3C). In insulin
tolerance tests, the effect of FGF21 was significantly reduced in
KOaP2 mice compared to control Klbfl/fl mice (Figure 3B). These
data show that bKlotho in adipose tissue is required for at least
part of the insulin-sensitizing effect of FGF21, but not the overall
growth effects of bKlotho that were observed in the whole-body
KO (compare Figure 2A to Figure S3C).
We performed similar experiments to assess insulin action
in diet-induced obese (DIO) Klbfl/fl and KOaP2 mice. DIO Klbfl/fl
and KOaP2 mice had similar body weights and composition (Fig-
ure S3D). Importantly, while KlbmRNAwas reduced by70% in
WAT from lean KOaP2 mice, it was virtually absent from WAT as
well as BAT of DIO KOaP2 mice (Figure 3C). Thus, the HFD
improves the efficiency by which aP2-Cre disrupts bKlotho
expression in WAT. Consistent with our previous findings in
Fgf21-KO mice (Dutchak et al., 2012), DIO KOaP2 mice had re-
duced expression of Pgc1a, Acaca, Scd1, and Pck1 in WAT (Fig-
ure S3E). Notably, the insulin-sensitizing effect of FGF21 was
completely lost in DIO KOaP2 mice (Figure 3D).
Complementary euglycemic-hyperinsulinemic clamp experi-
ments were performed to further evaluate the role of bKlotho in
adipose for mediating the insulin-sensitizing effect of FGF21.
DIO Klbfl/fl and KOaP2 mice were intravenously injected with
vehicle or FGF21 and then continuously infused with insulin inr Inc.
Figure 3. Acute Insulin-Sensitizing Effect of
FGF21 Is Absent in Mice Lacking bKlotho in
Adipose
(A) QPCR analysis of bKlotho (Klb) mRNA in in-
terscapular BAT, epididymal WAT, and liver in
normal chow-fed Klbfl/fl mice (fl/fl) (n = 5 mice/
group) or Klbfl/fl;aP2-Cre mice (KOaP2) mice (n = 7
mice/group).
(B) Insulin tolerance test (0.75 U/kg insulin) in
normal chow-fed mice coinjected with vehicle or
FGF21 (1 mg/kg, intraperitoneal injection) (n = 5–6
mice/group). *p < 0.05, ***p < 0.005 between
groups of fl/fl and KOaP2 mice treated with FGF21.
(C) QPCR analysis of Klb mRNA in interscapular
BAT, epididymal WAT, and liver in fl/fl mice (n = 6)
or KOaP2 mice (n = 4) fed a HFD.
(D) Insulin tolerance test (0.75 U/kg insulin) in HFD
mice coinjected with vehicle or FGF21 (1 mg/kg,
intraperitoneal injection) (n = 13/group for fl/fl Veh
and fl/fl FGF21; n = 11/group for KOaP2 and KOaP2
FGF21). **p < 0.01, ***p < 0.005 between groups of
fl/fl and KOaP2 mice treated with FGF21.
(E) Glucose infusion rate in HFD mice treated
with vehicle or FGF21 during a hyperinsulinemic-
euglycemic clamp (n = 6 mice/group). Different
letters indicate a significant difference (p < 0.05).
(F) Whole-body glucose uptake before and during
the clamp (n = 6 mice/group). *p < 0.05, between
groups of fl/fl treated with vehicle or FGF21.
(G) Tissue glucose uptake during the clamp (n = 6
mice/group). Gastroc., gastrocnemius. *p < 0.05,
between groups of fl/fl treated with vehicle or
FGF21.
(H) Endogenous glucose production before and
during the clamp (left) and suppression of
endogenous glucose production during the clamp
(right) (n = 6 mice/group).
Data are presented as the mean ± SEM.
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and insulin levels are shown in Table S1. In Klbfl/fl mice, FGF21
treatment increased the glucose infusion rate by 5-fold (Fig-
ure 3E). Under clamp conditions, FGF21 administration signifi-
cantly increased whole-body glucose uptake in Klbfl/fl but not
KOaP2 mice (Figure 3F). Analysis of different tissues showed
that glucose uptake was significantly increased only in BAT (Fig-
ure 3G). There were also trends toward decreased endogenous
glucose production and enhanced suppression of endogenous
glucose production in Klbfl/fl but not KOaP2 mice under clamp
conditions (Figure 3H). Taken together, these data highlight the
importance of adipose tissue in mediating the acute insulin-
sensitizing actions of FGF21. While our results showing that
FGF21 enhances insulin sensitivity might appear to contradict
the previous finding that FGF21 enhances hepatic gluconeogen-
esis (Potthoff et al., 2009), we note that these previous experi-
ments were done after chronic exposure to FGF21 and in the
absence of exogenous insulin. Since insulin suppresses gluco-
neogenesis, the insulin-sensitizing effect that we observed under
the current conditions is likely due to the combination of FGF21
stimulating glucose uptake in BAT and suppressing glucose
production in liver.Cell MeaP2-Cre mice also express Cre in the nervous system
(Martens et al., 2010). Since we found that bKlotho is expressed
in the suprachiasmatic nucleus in the hypothalamus and dorsal
vagal complex in the brainstem (Figure S3G), and intracerebro-
ventricular injection of FGF21 improves insulin sensitivity in
rats (Sarruf et al., 2010), we measured Klb mRNA levels in these
brain regions of KOaP2 mice. Klb expression was reduced in both
the suprachiasmatic nucleus and dorsal vagal complex in KOaP2
mice (Figure S3F). To determine whether bKlotho in the nervous
system contributes to the acute insulin-sensitizing actions of
FGF21, we crossedKlbfl/fl andCamK2a-Cremice, which express
Cre in the nervous system (Casanova et al., 2001), to generate
KOCamK2a mice. As shown in Figure S3G,CamK2a-Cre efficiently
reduced Klb mRNA expression in both the suprachiasmatic
nucleus and dorsal vagal complex, but not in BAT, WAT, or liver.
Klbfl/fl and KOCamK2a mice have similar body weights and body
composition either on normal chow or after HFD for 3 months
(data not shown). In insulin tolerance tests, DIO Klbfl/fl and
KOCamK2a mice showed identical response to FGF21 treatment
(Figure S3H). Thus, eliminating bKlotho in the nervous system
does not affect the acute insulin-sensitizing activity of FGF21.
aP2-Cre mice also express Cre in macrophages (Urs et al.,tabolism 16, 387–393, September 5, 2012 ª2012 Elsevier Inc. 391
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expressed in the stromal vascular fraction of adipose tissue or
in peritoneal, bone-marrow-derived, and spleen-derived macro-
phages (Figure S3I). These findings further support the conclu-
sion that the insulin-sensitizing effects of FGF21 require bKlotho
in adipose tissue.
In summary, we provide definitive evidence that bKlotho is
essential for the diverse actions of FGF21. We note that another
group, using an independently derived bKlotho-KO mouse line,
previously concluded that bKlotho is not required for at least
some of the actions of FGF21 (Tomiyama et al., 2010). However,
this group used unpurified, concentrated culture medium from
FGF21-overexpressingCHOcells as their source of recombinant
FGF21 and only examined the effect of this protein on a single
parameter, namely the induction of Egr1 expression in WAT
and BAT (Tomiyama et al., 2010). In contrast, using highly puri-
fied FGF21, we show that FGF21-mediated induction of Egr1
in WAT, BAT, and liver requires bKlotho. Importantly, we further
demonstrate that bKlotho is required for the metabolic actions of
FGF21 ranging from its insulin-sensitizing and lipid-lowering
actions to its inhibitory effects on growth. Finally, we demon-
strate that bKlotho in adipose tissue plays an important role in
mediating the acute effects of FGF21 on insulin sensitivity and
glucose uptake. While we were unable to determine definitively
whether these effects are mediated by FGF21 acting directly
on WAT or BAT, our data suggest that both tissues are likely to
be important. Two recent studies showed that the metabolic
effects of FGF21 are lost in lipodystrophic mice (Veniant et al.,
2012; Wu et al., 2011), providing additional and complementary
evidence that FGF21 acts on adipose tissue. Future studies will
be aimed at dissecting the contributions of the different types of
adipose tissue to the actions of FGF21.
EXPERIMENTAL PROCEDURES
Mouse Experiments
Fgf21-Tg, CamK2a-Cre, and Meox-Cre mice were previously described
(Casanova et al., 2001; Inagaki et al., 2007; Tallquist and Soriano, 2000).
aP2-Cre (#005069) and FLP mice (#003800) were purchased from Jackson
Labs. Mice were fed standard chow (Harlan Teklad, TD.2916) or a HFD
containing 60% fat (Research Diets, D12492i) ad libitum. All experiments
were performed with male mice and were approved by the Institutional Animal
Care and Research Advisory Committee of the University of Texas South-
western Medical Center.
Generation of bKlotho-KO Mice
The bKlotho-KO targeting vector was constructed as diagrammed in Fig-
ure S1A. The bKlotho gene was deleted in the germline by crossing Klbfl/+
micewithMeox-Cremice. aP2-Cre andCamK2a-Cremicewere used to delete
bKlotho in adipose tissue and the nervous system, respectively. All mice were
maintained on a mixed C57Bl/6;129/Sv background.
FGF21 Injection Experiments
Human FGF21 (residues 29–209) with a hexahistidine tag on the amino
terminus was expressed in E. coli, purified by sequential Ni chelating and
size-exclusion chromatography, and stored at 2–3 mg/ml in 25 mM HEPES
(pH 7.5), 150 mM NaCl, 50% glycerol. For acute studies, stock FGF21
(or vehicle) was diluted to 0.1 mg/ml in saline and injected intraperitoneally
at 1 mg/kg.
Body Composition Analysis
Body composition was measured using an EchoMRI-100 Body Composition
Analyzer (Houston).392 Cell Metabolism 16, 387–393, September 5, 2012 ª2012 ElsevieGlucose and Insulin Tolerance Tests
Glucose and insulin tolerance tests were performed on mice fasted for 16 and
4 hr, respectively.
Statistical Analyses
Statistical analyses were performed using Student’s t test (Microsoft Excel
2007). Data are presented as the mean ± SEM; p < 0.05 was considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2012.08.002.
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